William Blair Investment Management LLC Grows Position in Quanterix Corporation $QTRX

William Blair Investment Management LLC boosted its position in shares of Quanterix Corporation (NASDAQ:QTRX) by 16.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,315,280 shares of the company’s stock after buying an additional 187,299 shares during the quarter. William Blair Investment Management LLC’s holdings in Quanterix were worth $7,142,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in QTRX. Intech Investment Management LLC increased its position in shares of Quanterix by 13.4% in the third quarter. Intech Investment Management LLC now owns 19,161 shares of the company’s stock valued at $104,000 after acquiring an additional 2,268 shares during the period. Jane Street Group LLC raised its position in Quanterix by 4.2% during the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock valued at $380,000 after purchasing an additional 2,366 shares during the last quarter. Rhumbline Advisers lifted its holdings in Quanterix by 7.2% in the 2nd quarter. Rhumbline Advisers now owns 60,629 shares of the company’s stock worth $403,000 after buying an additional 4,094 shares during the period. American Century Companies Inc. increased its stake in shares of Quanterix by 9.0% during the second quarter. American Century Companies Inc. now owns 86,215 shares of the company’s stock valued at $573,000 after buying an additional 7,085 shares during the period. Finally, State of Wyoming raised its holdings in shares of Quanterix by 105.3% during the second quarter. State of Wyoming now owns 14,814 shares of the company’s stock valued at $99,000 after acquiring an additional 7,599 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on QTRX shares. Wall Street Zen upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, December 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group lifted their price objective on Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.33.

Quanterix Stock Performance

Shares of NASDAQ QTRX opened at $5.87 on Wednesday. The company has a 50 day simple moving average of $6.49 and a two-hundred day simple moving average of $6.01. Quanterix Corporation has a fifty-two week low of $4.05 and a fifty-two week high of $8.77. The company has a market capitalization of $274.19 million, a price-to-earnings ratio of -2.33 and a beta of 1.05.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). The company had revenue of $41.40 million for the quarter, compared to the consensus estimate of $37.95 million. Quanterix had a negative net margin of 77.14% and a negative return on equity of 23.72%. On average, analysts forecast that Quanterix Corporation will post -0.98 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.